Welcome to our dedicated page for Matinas BioPharma Holdings news (Ticker: MTNB), a resource for investors and traders seeking the latest updates and insights on Matinas BioPharma Holdings stock.
Matinas BioPharma Holdings, Inc. develops biopharmaceutical therapies using its lipid nanocrystal, or LNC, delivery technology. Company updates center on MAT2203, an oral formulation of amphotericin B for invasive fungal infections, along with broader LNC platform applications for intracellular delivery of small molecules and oligonucleotides.
Recurring MTNB news also covers operating and financial results, clinical and regulatory disclosures, governance changes, shareholder ownership activity, capital-structure matters, and NYSE American continued-listing compliance. The company’s announcements connect its drug-development work with board oversight, financing needs, and public-company requirements.
Matinas BioPharma Holdings (MTNB) announced that CEO Jerome D. Jabbour will present a company overview at the Jefferies Virtual Healthcare Conference on June 2, 2020, at 8:00 a.m. ET. He will also host investor meetings during this event. Interested investors can arrange meetings through the conference coordinator. A live webcast will be available on the company's IR calendar page, with a replay accessible for 90 days post-event. Matinas focuses on developing MAT9001 for cardiovascular and metabolic conditions and MAT2203 for serious fungal infections.
Summary not available.